FMCQF - Fresenius appoints head of pharma unit as new CEO
- German health services company Fresenius Medical Care AG & Co. ( NYSE: FMS ) ( OTCPK:FMCQF ) announced Friday that the head of its pharmaceutical division Michael Sen would become the company’s new Chief Executive effective Oct. 01.
- Sen will replace Fresenius’ ( FMS ) long-serving CEO Stephan Sturm who will leave the company on Sep. 30 after more than six years of service in the position.
- Sen, who has led the company’s drug division, Fresenius Kabi, since April 2021, will continue to serve as its CEO until a replacement is found.
- The 53-year-old joined Fresenius’ ( FMS ) management board in Apr. 2021 from Siemens AG, where he was responsible for the German conglomerate’s healthcare business, Siemens Healthineers, and its energy business.
- The leadership change comes after Fresenius ( FMS ) cut its 2022 outlook with its Q2 2022 financials in July.
For further details see:
Fresenius appoints head of pharma unit as new CEO